Clinical trial NCT00002163: A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
Official title: A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: AIDS Dementia Complex
HIV Infections
Keywords: Acquired Immunodeficiency Syndrome
AIDS Dementia Complex
Antiviral Agents
abacavir
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.

Detailed description: Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry and will then be stratified depending on whether their regimen contains zidovudine (ZDV). Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered.

Eligibility criteria: Inclusion Criteria

Patients must have:

* Documented HIV infection.
* Evidence of HIV - associated dementia.
* Been on stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

* Debilitated as a result of their HIV disease, associated illness or therapies who the investigator determines will not be able to complete the 12 week randomized dosing period.
* Memorial Sloan-Kettering (MSK) score of \>= 3 for dementia.
* Confounding neurological diseases which may interfere with interpretation of neurological and neurophysical assessments.
* Malabsorption syndrome or other gastrointestinal dysfunction which renders them unable to take oral medication.
* Chronic diseases such as diabetes, congestive heart failure, cardiomyopathy, other cardiac dysfunctions, etc., which in the investigator's opinion would compromise the safety of the patient.
* Symptomatic AIDS-defining opportunistic infection not responsive to therapy.

Concurrent Medication:

Excluded:

* Treatment with cytotoxic chemotherapeutic agents within the first 12 weeks of the study.
* Treatment with nerve growth factor within the first 12 weeks of study.
* The use of narcotic analgesics, sedatives, benzodiazepines, antidepressants, anti-psychotic agents and other psychoactive drugs which would interfere with the assessment of the neurological and neurophysical status of the patient.
* Use of stavudine (d4T) during the first 12 weeks of the study.
* Immunomodulating agents (except GM/G-CSF or epoietin).
* Psychoactive drugs (at the investigator's discretion).

Concurrent Treatment:

Excluded:

* Treatment with radiation therapy within the first 12 weeks of the study.

NOTE:

* With the exception of local treatment for Kaposi's sarcoma.

Patients with any of the following prior conditions are excluded:

* Previous neurological disease unrelated to HIV infection.
* History of clinically apparent hepatitis within the last 6 months.
* History of clinically apparent pancreatitis in the last 6 months.

Prior Medication:

Excluded:

* Treatment with cytotoxic chemotherapeutic agents within 1 month of entry.
* Participation in investigational antiretroviral trials within the past 3 months.
* HIV vaccine within the past 3 months.
* Treatment with immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry.
* Nerve growth factor.

Prior Treatment:

Excluded:

* Treatment with radiation therapy within 1 month of entry.

NOTE:

* With the exception of local treatment for Kaposi's sarcoma.

Risk Behavior:

Excluded:

Current alcohol or illicit drug use which may interfere with the patient's ability to comply with the study protocol.

Required:

* Stable antiretroviral treatment that has been ongoing for a minimum of 6 weeks prior to study entry, may or may not include ZDV.

Required:

* Stable antiretroviral treatment for a minimum of 6 weeks prior to study entry.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: HIV Neurobehavioral Research Ctr
state: California
city: San Francisco
country: United States
facility: San Francisco Gen Hosp
state: California
city: Baltimore
country: United States
facility: Johns Hopkins Univ School of Medicine
state: Maryland
city: St Louis
country: United States
facility: Washington Univ Med Ctr
state: Missouri
city: New York
country: United States
facility: Mount Sinai Med Ctr
state: New York
city: New York
country: United States
facility: Columbia Univ / Sergievsky Ctr
state: New York
city: Chapel Hill
country: United States
facility: Univ of North Carolina School of Medicine
state: North Carolina
city: Winnipeg
country: Canada
facility: Univ of Manitoba / Faculty of Medicine
state: Manitoba
city: Toronto
country: Canada
facility: Wellesley Hosp
state: Ontario
Study officials:
References:
citation: Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW, Simpson D, Torres G, Catalan J, Marder K, Power C, Hall C, Romero C, Brew B. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS. 2001 Apr 13;15(6):747-51. doi: 10.1097/00002030-200104130-00010.